AR080895A1 - Formulacion de comprimido de ezatiostat - Google Patents
Formulacion de comprimido de ezatiostatInfo
- Publication number
- AR080895A1 AR080895A1 ARP110101257A ARP110101257A AR080895A1 AR 080895 A1 AR080895 A1 AR 080895A1 AR P110101257 A ARP110101257 A AR P110101257A AR P110101257 A ARP110101257 A AR P110101257A AR 080895 A1 AR080895 A1 AR 080895A1
- Authority
- AR
- Argentina
- Prior art keywords
- ezatiostat
- compressed formulation
- tablet
- pharmaceutically acceptable
- croscarmellose sodium
- Prior art date
Links
- GWEJFLVSOGNLSS-WPFOTENUSA-N ethyl (2s)-2-amino-5-[[(2r)-3-benzylsulfanyl-1-[[(1r)-2-ethoxy-2-oxo-1-phenylethyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoate Chemical compound C([C@H](NC(=O)CC[C@H](N)C(=O)OCC)C(=O)N[C@@H](C(=O)OCC)C=1C=CC=CC=1)SCC1=CC=CC=C1 GWEJFLVSOGNLSS-WPFOTENUSA-N 0.000 title 1
- 229950003030 ezatiostat Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 2
- 229960001681 croscarmellose sodium Drugs 0.000 abstract 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 2
- XJDYQYNYISTAMO-GFDYFVENSA-N ethyl (2s)-2-amino-5-[[(2r)-3-benzylsulfanyl-1-[[(1r)-2-ethoxy-2-oxo-1-phenylethyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoate;hydrochloride Chemical compound Cl.C([C@H](NC(=O)CC[C@H](N)C(=O)OCC)C(=O)N[C@@H](C(=O)OCC)C=1C=CC=CC=1)SCC1=CC=CC=C1 XJDYQYNYISTAMO-GFDYFVENSA-N 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 229960003943 hypromellose Drugs 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 229960001855 mannitol Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35237710P | 2010-06-07 | 2010-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080895A1 true AR080895A1 (es) | 2012-05-16 |
Family
ID=42829329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101257A AR080895A1 (es) | 2010-06-07 | 2011-04-13 | Formulacion de comprimido de ezatiostat |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20110300215A1 (enExample) |
| EP (1) | EP2576591A2 (enExample) |
| JP (1) | JP2013528213A (enExample) |
| CN (1) | CN102917694A (enExample) |
| AR (1) | AR080895A1 (enExample) |
| CA (1) | CA2797458A1 (enExample) |
| TW (1) | TW201143761A (enExample) |
| WO (1) | WO2011156045A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012151051A1 (en) * | 2011-05-03 | 2012-11-08 | Telik, Inc. | Excipient compatibility with ezatiostat |
| US20130035389A1 (en) | 2011-08-05 | 2013-02-07 | Telik, Inc. | Methods for treating myelodysplastic syndrome with ezatiostat |
| US10156885B2 (en) | 2014-04-07 | 2018-12-18 | Avago Technologies International Sales Pte. Limited | Network energy consumption reduction |
| WO2016117927A1 (ko) | 2015-01-20 | 2016-07-28 | 주식회사 한림포스텍 | 무선 전력 전송 장치 및 이의 전송 전력 제어 방법 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5599903A (en) | 1992-04-03 | 1997-02-04 | Terrapin Technologies, Inc. | Glutathione analogs and paralog panels comprising glutathione mimics |
| US5114003A (en) * | 1991-03-28 | 1992-05-19 | E. I. Du Pont De Nemours And Company | Tablet vial with desiccant in bottom |
| US5786336A (en) | 1991-04-29 | 1998-07-28 | Terrapin Technologies, Inc. | Target-selective protocols based on mimics |
| US5955432A (en) * | 1992-04-03 | 1999-09-21 | Terrapin Technologies, Inc. | Metabolic effects of certain glutathione analogs |
| US5965164A (en) | 1994-10-28 | 1999-10-12 | Fuisz Technologies Ltd. | Recipient-dosage delivery system |
| US6627732B1 (en) * | 1998-04-16 | 2003-09-30 | Teijin Limited | Glutathione derivatives and their dosage forms |
| WO2002088664A2 (en) * | 2001-04-26 | 2002-11-07 | Bristol-Myers Squibb Company | Control of compactability through crystallization |
| US7029695B2 (en) | 2001-07-10 | 2006-04-18 | Telik, Inc. | Therapeutic compositions containing glutathione analogs |
| US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
| WO2005065639A2 (en) | 2003-11-21 | 2005-07-21 | Torrent Pharmaceuticals Limited | Novel pharmaceutical compositions |
| CN101133020A (zh) * | 2004-12-03 | 2008-02-27 | 特瓦制药工业有限公司 | 依泽替米贝多晶型 |
| HRP20090128T3 (hr) * | 2005-01-06 | 2009-04-30 | Telik Inc. | Tripeptid i tetrapeptid tioeteri |
| EP1880722B1 (en) | 2006-07-19 | 2010-03-17 | Tabuk Pharmaceutical Manufacturing Co. | Pharmaceutical compositions of ciprofloxacin |
| EP2125715A2 (en) * | 2007-01-24 | 2009-12-02 | Krka | Process for the preparation of ezetimibe and derivatives thereof |
| EP2114380A1 (en) | 2007-01-25 | 2009-11-11 | Panacea Biotec Ltd. | Modified release pharmaceutical composition and a process of making the same |
| MX2010001711A (es) | 2007-08-13 | 2010-03-11 | Panacea Biotec Ltd | Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas. |
| AR068745A1 (es) | 2007-10-08 | 2009-12-02 | Panacea Biotec Ltd | Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos |
-
2011
- 2011-03-29 EP EP11713930.3A patent/EP2576591A2/en not_active Withdrawn
- 2011-03-29 WO PCT/US2011/030376 patent/WO2011156045A2/en not_active Ceased
- 2011-03-29 JP JP2013514169A patent/JP2013528213A/ja not_active Withdrawn
- 2011-03-29 CN CN2011800272195A patent/CN102917694A/zh active Pending
- 2011-03-29 US US13/075,116 patent/US20110300215A1/en not_active Abandoned
- 2011-03-29 CA CA2797458A patent/CA2797458A1/en not_active Abandoned
- 2011-04-01 TW TW100111502A patent/TW201143761A/zh unknown
- 2011-04-13 AR ARP110101257A patent/AR080895A1/es unknown
- 2011-09-27 US US13/246,732 patent/US8361971B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011156045A2 (en) | 2011-12-15 |
| US20120021054A1 (en) | 2012-01-26 |
| CA2797458A1 (en) | 2011-12-15 |
| US8361971B2 (en) | 2013-01-29 |
| EP2576591A2 (en) | 2013-04-10 |
| JP2013528213A (ja) | 2013-07-08 |
| TW201143761A (en) | 2011-12-16 |
| US20110300215A1 (en) | 2011-12-08 |
| CN102917694A (zh) | 2013-02-06 |
| WO2011156045A3 (en) | 2012-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200600008A (es) | Formulacion de compresion directa y proceso | |
| FI3182975T3 (fi) | Rukaparibin suuren annosvahvuuden tabletteja | |
| BR112017006957A2 (pt) | formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína | |
| PE20142440A1 (es) | Composiciones farmaceuticas orales de liberacion inmediata con recubrimiento no enterico que comprende 5-azacitidina | |
| AR077546A1 (es) | Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos | |
| GT200600096A (es) | Composicion farmaceutica para el tratamiento del cancer | |
| EA201291410A1 (ru) | Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат | |
| NZ625087A (en) | Combination formulation of two antiviral compounds | |
| HRP20192026T4 (hr) | Formulacija tableta od neratinib maleata | |
| UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
| AR094548A1 (es) | Dispersión sólida físicamente estable | |
| UA116334C2 (uk) | Тверді форми дозування бендамустину | |
| CL2013000677A1 (es) | Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn. | |
| CU24619B1 (es) | Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración por via oral | |
| BR112015021112A2 (pt) | composições farmacêuticas que compreendem everolimo | |
| AR107391A1 (es) | Formulaciones / composiciones que comprenden un inhibidor de btk | |
| AR100977A1 (es) | Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación | |
| TN2015000135A1 (en) | Modified release formulations for oprozomib | |
| AR080895A1 (es) | Formulacion de comprimido de ezatiostat | |
| ECSP15022442A (es) | Producto de comicronización que comprende acetato de ulipristal | |
| PE20131035A1 (es) | Formulacion de nevirapina de liberacion prolongada | |
| MY139086A (en) | Use of debranched starch in extrusion-spheronization pharmaceutical pellets | |
| CO6280494A2 (es) | Composiciones que comprenden euphorbia prostrata y procesos de preparacion de las mismas | |
| ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
| BR112012012766A2 (pt) | composicões farmacêuticas de galantamina de liberação controlada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |